You are here: Industry Insights > EUSA Pharma

News List

Recordati to acquire EUSA Pharma to expand rare disease products portfolio Pharmaceutical-Technology
December 06, 2021
Italian company Recordati has signed an agreement to acquire EUSA Pharma in a deal worth about $848.9m (€750m) to expand its rare disease products portfolio.
EUSA Pharma launches phase III COVID-19 study for siltuximab pharmatimes
December 18, 2020
UK-headquartered EUSA Pharma has enrolled the first patient in a phase III study of siltuximab in patients hospitalised with COVID-19.
EUSA Pharma bags US approval for COVID-19 trial pharmatimes
July 03, 2020
US regulators have issued a green light for a Phase III clinical trial testing EUSA Pharma's for patients seriously ill with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
Study evaluates if siltuximab benefits COVID-19 patients with respiratory complications europeanpharmaceuticalreview
March 23, 2020
The SISCO study will assess if the anti-IL-6 antibody siltuximab can aid patients suffering Acute Respiratory Distress Syndrome as a complication of the COVID-19 coronavirus.
AVEO Oncology warns of "regulatory action" by EMA if overall survival results for Fotivda come up short pharmatimes
April 04, 2019
AVEO Oncology disclosed in a filing with the US Securities and Exchange Commission that the European Medicines Agency will consider "regulatory action" if an interim overall survival (OS) analysis from the TIVO-3 trial confirms a negative trend for Fotivd
EUSA Pharma Appoints President of US Operations americanpharmaceuticalreview
December 06, 2018
EUSA Pharma, a global biopharmaceutical company with a focus on oncology and rare disease, has announced the appointment of Jeffrey S. Hackman as President.....
Aveo's phoenix drug tivozanib rises up in Europe fiercebiotech
August 29, 2017
EUSA Pharma says it will make the drug available to kidney cancer patients across Europe "as quickly as possible."